NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. [electronic resource]
- Cancer letters Oct 2015
- 58-68 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1872-7980
10.1016/j.canlet.2015.07.007 doi
Animals Antineoplastic Agents, Alkylating--pharmacology Antineoplastic Combined Chemotherapy Protocols--pharmacology Apoptosis--drug effects Brain Neoplasms--drug therapy Caspase 3--metabolism Cell Line, Tumor Cell Proliferation--drug effects Dacarbazine--analogs & derivatives Dose-Response Relationship, Drug Drug Resistance, Neoplasm--drug effects Drug Synergism G1 Phase Cell Cycle Checkpoints--drug effects Glioma--drug therapy Humans Imidazoles--pharmacology Inhibitory Concentration 50 Male Mice, SCID Phosphatidylinositol 3-Kinase--metabolism Phosphoinositide-3 Kinase Inhibitors Phosphorylation Protein Kinase Inhibitors--pharmacology Proto-Oncogene Proteins c-akt--metabolism Quinolines--pharmacology Signal Transduction--drug effects TOR Serine-Threonine Kinases--antagonists & inhibitors Temozolomide Tumor Burden--drug effects Xenograft Model Antitumor Assays bcl-2-Associated X Protein--metabolism